Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Joseph Saseen

Concepts (461)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Hydroxymethylglutaryl-CoA Reductase Inhibitors
29
2025
454
5.230
 Why?
Atherosclerosis
9
2025
404
3.480
 Why?
Cardiovascular Diseases
24
2025
2096
2.920
 Why?
Cholesterol, LDL
15
2025
361
2.880
 Why?
Pharmacists
18
2025
263
2.840
 Why?
Hypertension
23
2024
1254
2.790
 Why?
Antihypertensive Agents
14
2024
508
2.630
 Why?
Hypercholesterolemia
9
2025
101
1.890
 Why?
Students, Pharmacy
8
2025
105
1.810
 Why?
Educational Measurement
6
2025
319
1.570
 Why?
Education, Pharmacy
8
2025
133
1.530
 Why?
Hypolipidemic Agents
8
2021
92
1.420
 Why?
Blood Pressure
12
2024
1748
1.400
 Why?
Anticholesteremic Agents
8
2025
155
1.360
 Why?
Professional Role
7
2020
168
1.360
 Why?
Practice Patterns, Physicians'
6
2025
1344
1.350
 Why?
Dyslipidemias
8
2025
175
1.350
 Why?
Medication Therapy Management
5
2018
79
1.190
 Why?
Practice Guidelines as Topic
12
2020
1570
1.180
 Why?
Cholesterol
5
2020
405
1.060
 Why?
Lipids
3
2022
690
1.050
 Why?
Calcium Channel Blockers
7
2015
172
1.020
 Why?
Ambulatory Care
9
2018
587
1.020
 Why?
Managed Care Programs
4
2014
140
1.010
 Why?
Humans
141
2026
141754
0.960
 Why?
Gout
4
2025
38
0.940
 Why?
Societies, Pharmaceutical
7
2017
21
0.930
 Why?
Renal Insufficiency, Chronic
2
2025
623
0.900
 Why?
Chlorthalidone
2
2014
5
0.900
 Why?
Hydrochlorothiazide
2
2014
9
0.900
 Why?
Arthritis, Gouty
2
2016
15
0.880
 Why?
Pharmaceutical Services
5
2020
87
0.880
 Why?
Retrospective Studies
38
2025
16374
0.870
 Why?
Adrenergic beta-Antagonists
4
2014
228
0.840
 Why?
Anti-Inflammatory Agents, Non-Steroidal
5
2018
348
0.820
 Why?
Education, Pharmacy, Graduate
4
2017
16
0.800
 Why?
Aged
42
2025
24746
0.790
 Why?
Pharmacy Residencies
3
2018
11
0.790
 Why?
Urinary Tract Infections
2
2023
194
0.790
 Why?
American Heart Association
4
2020
296
0.770
 Why?
Dicarboxylic Acids
2
2025
12
0.760
 Why?
Diabetes Mellitus
4
2023
1077
0.740
 Why?
Middle Aged
46
2026
34647
0.740
 Why?
Primary Health Care
10
2025
1809
0.720
 Why?
Blood Glucose
4
2017
2278
0.710
 Why?
Clinical Competence
4
2018
1205
0.700
 Why?
Diuretics
4
2014
73
0.700
 Why?
Coronary Artery Disease
3
2021
702
0.690
 Why?
Serotonin 5-HT1 Receptor Agonists
1
2020
4
0.690
 Why?
Preceptorship
2
2018
68
0.690
 Why?
Angiotensin-Converting Enzyme Inhibitors
5
2011
198
0.680
 Why?
Evidence-Based Medicine
14
2018
750
0.680
 Why?
Drug Prescriptions
2
2020
267
0.670
 Why?
Gout Suppressants
3
2025
21
0.650
 Why?
Teaching
3
2018
237
0.650
 Why?
Diabetes Mellitus, Type 2
7
2022
2537
0.650
 Why?
Muscular Diseases
2
2015
113
0.630
 Why?
Hypoglycemic Agents
4
2014
1374
0.620
 Why?
Proton Pump Inhibitors
2
2024
109
0.610
 Why?
Migraine Disorders
1
2020
107
0.610
 Why?
Fatty Acids
2
2025
450
0.600
 Why?
Health Benefit Plans, Employee
2
2017
27
0.590
 Why?
Aged, 80 and over
17
2025
7923
0.590
 Why?
Emergency Service, Hospital
2
2020
2193
0.580
 Why?
Drug Therapy
2
2017
86
0.580
 Why?
Female
57
2026
75943
0.560
 Why?
Acetaminophen
3
2007
264
0.560
 Why?
Male
52
2026
70179
0.560
 Why?
Text Messaging
3
2025
179
0.550
 Why?
Insurance Coverage
2
2011
239
0.550
 Why?
Simvastatin
3
2015
63
0.530
 Why?
Primary Prevention
4
2025
202
0.530
 Why?
Faculty, Pharmacy
1
2017
21
0.510
 Why?
Schools, Pharmacy
1
2017
49
0.510
 Why?
Adult
35
2026
39391
0.510
 Why?
Research
2
2017
455
0.500
 Why?
Population Health
1
2017
48
0.490
 Why?
HIV
1
2017
250
0.490
 Why?
Cardiology
4
2018
280
0.480
 Why?
Heart Failure
3
2023
2093
0.470
 Why?
Hyperlipidemias
5
2018
125
0.460
 Why?
Monitoring, Physiologic
1
2017
285
0.460
 Why?
Anti-Retroviral Agents
1
2017
245
0.460
 Why?
Antipsychotic Agents
1
2017
212
0.460
 Why?
Perception
1
2018
378
0.460
 Why?
Treatment Outcome
18
2025
11181
0.440
 Why?
Proprotein Convertase 9
5
2025
87
0.440
 Why?
Faculty, Medical
1
2017
296
0.430
 Why?
Angiotensin II Type 1 Receptor Blockers
2
2013
38
0.430
 Why?
Poverty
2
2008
530
0.420
 Why?
United States
24
2025
15310
0.420
 Why?
Program Evaluation
3
2017
930
0.420
 Why?
Analgesics, Non-Narcotic
2
2007
127
0.420
 Why?
Gastrointestinal Hemorrhage
2
2024
134
0.420
 Why?
Aspirin
3
2024
385
0.410
 Why?
Risk Factors
18
2025
10482
0.410
 Why?
Drug Therapy, Combination
12
2020
1041
0.410
 Why?
Tetrazoles
1
2013
45
0.410
 Why?
Ezetimibe
4
2021
25
0.400
 Why?
Colorado
14
2026
4629
0.400
 Why?
Guideline Adherence
4
2025
566
0.390
 Why?
Xanthine Oxidase
3
2025
81
0.390
 Why?
Adrenal Cortex Hormones
2
2016
501
0.390
 Why?
Self Report
1
2017
861
0.390
 Why?
Gemfibrozil
3
2016
11
0.390
 Why?
Anti-Arrhythmia Agents
2
2003
112
0.390
 Why?
Glomerular Filtration Rate
3
2025
752
0.390
 Why?
Curriculum
6
2018
1039
0.380
 Why?
Osteoarthritis
2
2006
199
0.380
 Why?
Venoms
1
2012
28
0.380
 Why?
Imidazoles
1
2013
255
0.370
 Why?
Analgesics, Opioid
1
2020
1123
0.370
 Why?
Health Expenditures
5
2017
193
0.360
 Why?
Lipoprotein(a)
2
2022
68
0.350
 Why?
Kidney
1
2019
1482
0.340
 Why?
Problem-Based Learning
3
2017
99
0.340
 Why?
Health Resources
1
2012
129
0.340
 Why?
Medication Adherence
2
2025
513
0.340
 Why?
Electronic Health Records
5
2018
1132
0.340
 Why?
Medicare Part D
1
2011
25
0.340
 Why?
Risk Assessment
11
2022
3508
0.330
 Why?
Arthritis, Rheumatoid
3
2009
1178
0.310
 Why?
Insurance Claim Review
3
2017
85
0.310
 Why?
Azetidines
2
2008
46
0.310
 Why?
Young Adult
10
2025
13749
0.310
 Why?
Patient Care Team
5
2024
673
0.310
 Why?
Rosuvastatin Calcium
2
2025
21
0.300
 Why?
Societies, Medical
5
2025
859
0.300
 Why?
Drug Interactions
4
2022
406
0.300
 Why?
Reminder Systems
3
2025
174
0.290
 Why?
Antirheumatic Agents
2
2009
298
0.290
 Why?
Prescription Drugs
2
2026
116
0.290
 Why?
Clinical Trials as Topic
8
2017
1057
0.280
 Why?
Community Health Centers
2
2018
63
0.280
 Why?
Age Factors
5
2017
3294
0.280
 Why?
Antibodies, Monoclonal
4
2020
1474
0.280
 Why?
Consensus
4
2025
547
0.280
 Why?
Cohort Studies
10
2020
5815
0.270
 Why?
Drug Costs
2
2006
116
0.260
 Why?
Venous Thromboembolism
2
2022
337
0.260
 Why?
HIV Infections
2
2023
3022
0.260
 Why?
Platelet Aggregation Inhibitors
2
2024
475
0.260
 Why?
Verapamil
2
1997
40
0.260
 Why?
Dipeptidyl-Peptidase IV Inhibitors
1
2007
48
0.260
 Why?
Family Practice
4
2015
464
0.250
 Why?
Tablets
1
2006
41
0.250
 Why?
Liver Diseases, Alcoholic
1
2007
94
0.250
 Why?
Weight Loss
3
2012
791
0.250
 Why?
Peptides
1
2012
979
0.250
 Why?
Kidney Failure, Chronic
2
2010
599
0.250
 Why?
Certification
2
2006
119
0.250
 Why?
Drug Utilization
2
2026
169
0.250
 Why?
Cyclooxygenase 2 Inhibitors
1
2006
22
0.250
 Why?
Renal Dialysis
1
2010
457
0.240
 Why?
Drug Compounding
1
2006
104
0.240
 Why?
Civil Defense
1
2026
22
0.240
 Why?
Sodium Chloride, Dietary
1
2006
31
0.240
 Why?
Lipoproteins
1
2007
163
0.240
 Why?
Chemical and Drug Induced Liver Injury
2
2007
138
0.240
 Why?
Patient Care
3
2017
120
0.240
 Why?
Randomized Controlled Trials as Topic
7
2007
1634
0.230
 Why?
Enzyme Inhibitors
2
2025
855
0.230
 Why?
Benzothiadiazines
1
2005
3
0.230
 Why?
Insurance, Health
4
2015
299
0.230
 Why?
Sodium Chloride Symporter Inhibitors
1
2005
9
0.230
 Why?
Blood Pressure Determination
3
2018
145
0.230
 Why?
Ambulatory Care Facilities
2
2017
248
0.230
 Why?
Education, Distance
1
2025
56
0.220
 Why?
Brain Ischemia
1
2008
350
0.220
 Why?
Drug Labeling
3
2015
40
0.220
 Why?
Quality Assurance, Health Care
1
2006
333
0.220
 Why?
Bronchiolitis, Viral
1
2004
11
0.210
 Why?
Fatty Acids, Omega-3
1
2025
142
0.210
 Why?
Adolescent
8
2025
22130
0.210
 Why?
Patient-Centered Care
3
2015
550
0.210
 Why?
Delivery of Health Care
4
2026
962
0.200
 Why?
Off-Label Use
2
2015
53
0.200
 Why?
Contraceptive Agents
1
2004
66
0.200
 Why?
Epinephrine
1
2004
148
0.200
 Why?
Cardiovascular Agents
1
2025
156
0.200
 Why?
Progesterone Congeners
1
2003
15
0.200
 Why?
Life Style
1
2006
482
0.200
 Why?
Medroxyprogesterone
1
2003
12
0.200
 Why?
Hormone Replacement Therapy
1
2004
102
0.200
 Why?
Incidence
3
2023
2806
0.200
 Why?
Quality Indicators, Health Care
1
2005
308
0.200
 Why?
Secondary Prevention
3
2024
241
0.190
 Why?
Estrogens, Conjugated (USP)
1
2003
51
0.190
 Why?
Bronchodilator Agents
1
2004
196
0.190
 Why?
Faculty
2
2018
154
0.190
 Why?
Health Knowledge, Attitudes, Practice
2
2025
1406
0.190
 Why?
C-Reactive Protein
1
2005
424
0.190
 Why?
Heart Conduction System
1
2003
89
0.190
 Why?
Tumor Necrosis Factor-alpha
1
2007
1250
0.190
 Why?
Program Development
2
2017
368
0.190
 Why?
Death, Sudden, Cardiac
1
2003
191
0.180
 Why?
Contraception
1
2004
166
0.180
 Why?
Estrogen Replacement Therapy
1
2003
142
0.180
 Why?
Attitude to Health
1
2005
458
0.180
 Why?
Antiphospholipid Syndrome
1
2021
31
0.180
 Why?
Atenolol
2
2014
8
0.170
 Why?
Artificial Intelligence
1
2025
337
0.170
 Why?
Communicable Diseases
1
2023
161
0.170
 Why?
Dietary Supplements
1
2025
570
0.170
 Why?
Vasodilator Agents
1
2003
330
0.170
 Why?
Uric Acid
2
2025
164
0.170
 Why?
Drug Tolerance
1
2021
105
0.170
 Why?
Pre-Exposure Prophylaxis
1
2023
240
0.160
 Why?
Public Health Administration
1
2021
74
0.160
 Why?
Costs and Cost Analysis
3
2014
222
0.160
 Why?
Transition to Adult Care
1
2022
92
0.160
 Why?
Diabetic Nephropathies
1
2004
299
0.160
 Why?
Dipyrone
1
1999
2
0.160
 Why?
Methenamine
1
2019
5
0.160
 Why?
Dose-Response Relationship, Drug
4
2014
2064
0.160
 Why?
Appetite Stimulants
1
1999
2
0.160
 Why?
HIV Wasting Syndrome
1
1999
4
0.160
 Why?
Pharmacy Service, Hospital
2
2013
87
0.160
 Why?
Diltiazem
2
1996
19
0.160
 Why?
Anabolic Agents
1
1999
13
0.160
 Why?
Anti-Infective Agents, Urinary
1
2019
17
0.160
 Why?
Nifedipine
2
1996
29
0.160
 Why?
Stroke
1
2008
1158
0.160
 Why?
Drug and Narcotic Control
1
1999
29
0.160
 Why?
Cross-Sectional Studies
4
2025
5697
0.160
 Why?
Heart Rate
1
2003
821
0.150
 Why?
Internship, Nonmedical
3
2011
13
0.150
 Why?
Patient Education as Topic
3
2024
779
0.150
 Why?
Protons
1
2019
94
0.150
 Why?
Atrial Fibrillation
1
2003
384
0.140
 Why?
Federal Government
1
2018
27
0.140
 Why?
Guidelines as Topic
2
2019
275
0.140
 Why?
Training Support
1
2018
37
0.140
 Why?
Health Services
2
2009
118
0.140
 Why?
Acquired Immunodeficiency Syndrome
1
1999
235
0.140
 Why?
Risk
2
2017
907
0.140
 Why?
Medically Underserved Area
1
2018
100
0.130
 Why?
Thrombosis
1
2021
399
0.130
 Why?
Peripheral Arterial Disease
1
2024
490
0.130
 Why?
Surveys and Questionnaires
3
2025
5974
0.130
 Why?
Models, Econometric
1
2017
36
0.130
 Why?
Severity of Illness Index
3
2019
2903
0.130
 Why?
Quality of Health Care
2
2017
658
0.130
 Why?
Vulnerable Populations
1
2018
170
0.130
 Why?
Anticoagulants
4
2022
675
0.130
 Why?
Colchicine
1
2016
23
0.130
 Why?
Protease Inhibitors
1
2017
105
0.130
 Why?
Warfarin
3
2021
153
0.130
 Why?
United States Food and Drug Administration
2
2015
212
0.130
 Why?
Hyperuricemia
1
2016
45
0.120
 Why?
Chronic Disease
3
2013
1820
0.120
 Why?
Anti-HIV Agents
1
2023
860
0.120
 Why?
Point-of-Care Systems
1
2018
188
0.120
 Why?
Alcoholism
1
2003
823
0.120
 Why?
Comorbidity
4
2016
1664
0.120
 Why?
Biomarkers
6
2025
4190
0.120
 Why?
Amlodipine
1
2015
10
0.110
 Why?
Pharmacovigilance
1
2015
24
0.110
 Why?
Education, Medical, Undergraduate
1
2017
196
0.110
 Why?
Liver
1
2003
1820
0.110
 Why?
Systole
1
2014
175
0.110
 Why?
Ethanolamines
1
2014
15
0.110
 Why?
Nebivolol
1
2014
10
0.110
 Why?
Metoprolol
1
2014
26
0.110
 Why?
Benzopyrans
1
2014
30
0.110
 Why?
Propanolamines
1
2014
39
0.110
 Why?
Exercise
1
2006
2112
0.100
 Why?
Carbazoles
1
2014
56
0.100
 Why?
Geriatrics
2
2025
93
0.100
 Why?
Risk Reduction Behavior
3
2022
227
0.100
 Why?
Losartan
1
2013
14
0.100
 Why?
Follow-Up Studies
3
2016
5212
0.100
 Why?
Valsartan
1
2013
30
0.100
 Why?
Valine
1
2013
77
0.100
 Why?
Medicaid
1
2017
451
0.100
 Why?
Drug Substitution
1
2013
60
0.100
 Why?
Biphenyl Compounds
1
2013
71
0.100
 Why?
Antidepressive Agents, Second-Generation
2
2004
50
0.100
 Why?
Fibric Acids
1
2012
3
0.090
 Why?
Contraindications
1
2012
85
0.090
 Why?
Socioeconomic Factors
1
2017
1317
0.090
 Why?
Drug Combinations
2
2016
368
0.090
 Why?
Telemedicine
1
2021
894
0.090
 Why?
Patient Acceptance of Health Care
2
2012
881
0.090
 Why?
Reproducibility of Results
3
2005
3356
0.090
 Why?
Age Distribution
1
2012
397
0.090
 Why?
Double-Blind Method
4
2003
1989
0.090
 Why?
Internship and Residency
2
2017
1240
0.090
 Why?
Vascular Endothelial Growth Factor A
1
2014
554
0.090
 Why?
Annual Reports as Topic
1
2010
3
0.090
 Why?
Professional Staff Committees
1
2010
12
0.090
 Why?
Decision Support Systems, Clinical
1
2015
263
0.090
 Why?
Financing, Personal
1
2011
28
0.090
 Why?
Sex Factors
1
2017
2063
0.080
 Why?
Insurance Benefits
1
2010
12
0.080
 Why?
Insurance, Pharmaceutical Services
1
2010
24
0.080
 Why?
Interpersonal Relations
1
2014
411
0.080
 Why?
Acute Kidney Injury
1
2018
820
0.080
 Why?
Pharmacy
1
2010
32
0.080
 Why?
Creatinine
1
2012
490
0.080
 Why?
Analysis of Variance
1
2012
1321
0.080
 Why?
Drug Utilization Review
2
2006
61
0.080
 Why?
Nutrition Surveys
2
2021
280
0.080
 Why?
Hyperlipoproteinemia Type II
2
2019
32
0.070
 Why?
Hypoglycemia
1
2014
468
0.070
 Why?
Dipyridamole
1
2008
29
0.070
 Why?
Ezetimibe, Simvastatin Drug Combination
1
2008
1
0.070
 Why?
Fluorobenzenes
1
2008
17
0.070
 Why?
Ticlopidine
1
2008
52
0.070
 Why?
Drug Administration Schedule
2
2007
771
0.070
 Why?
Internet
2
2025
690
0.070
 Why?
Abatacept
1
2007
56
0.070
 Why?
Ischemic Attack, Transient
1
2008
70
0.070
 Why?
Patient Compliance
3
2008
611
0.070
 Why?
Antibodies, Monoclonal, Murine-Derived
1
2007
96
0.070
 Why?
Adamantane
1
2007
18
0.070
 Why?
Dipeptidyl Peptidase 4
1
2007
15
0.070
 Why?
Proportional Hazards Models
1
2011
1268
0.070
 Why?
Timolol
1
2007
15
0.070
 Why?
Propranolol
1
2007
45
0.070
 Why?
Contraception, Postcoital
1
2007
9
0.060
 Why?
Accreditation
1
2007
93
0.060
 Why?
Hemorrhage
2
2022
760
0.060
 Why?
Community Pharmacy Services
1
2007
49
0.060
 Why?
Levonorgestrel
1
2007
36
0.060
 Why?
Rituximab
1
2007
205
0.060
 Why?
Pyrrolidines
1
2007
111
0.060
 Why?
Specialty Boards
1
2006
39
0.060
 Why?
Anti-Ulcer Agents
1
2006
15
0.060
 Why?
Immunoconjugates
1
2007
125
0.060
 Why?
Nitriles
1
2007
188
0.060
 Why?
Cost Savings
1
2006
86
0.060
 Why?
Medication Errors
1
2006
97
0.060
 Why?
Safety Management
1
2006
126
0.060
 Why?
Interrupted Time Series Analysis
1
2026
80
0.060
 Why?
Case Management
1
2005
67
0.060
 Why?
Pandemics
2
2026
1656
0.060
 Why?
Efficiency, Organizational
1
2005
139
0.060
 Why?
Pharmaceutical Preparations
1
2006
178
0.060
 Why?
Benchmarking
1
2005
180
0.050
 Why?
Pyrimidines
1
2008
512
0.050
 Why?
Nephrology
1
2005
61
0.050
 Why?
Sulfonamides
1
2008
567
0.050
 Why?
Professional-Patient Relations
1
2005
151
0.050
 Why?
Albuterol
1
2004
75
0.050
 Why?
Rhabdomyolysis
1
2003
24
0.050
 Why?
Coronary Disease
2
2003
371
0.050
 Why?
Amiodarone
1
2003
27
0.050
 Why?
Child, Preschool
2
2017
11512
0.050
 Why?
Longitudinal Studies
1
2011
2938
0.050
 Why?
Medicare
1
2009
808
0.050
 Why?
Meta-Analysis as Topic
1
2004
185
0.050
 Why?
Disease Susceptibility
1
2005
353
0.050
 Why?
Liver Function Tests
1
2003
105
0.050
 Why?
Antineoplastic Agents
1
2014
2169
0.050
 Why?
Nocebo Effect
1
2022
4
0.050
 Why?
Endpoint Determination
1
2003
78
0.050
 Why?
Sodium Potassium Chloride Symporter Inhibitors
1
2022
16
0.050
 Why?
Cyclohexanols
1
2002
13
0.050
 Why?
Vaginal Diseases
1
2002
20
0.050
 Why?
Physician-Patient Relations
1
2006
585
0.040
 Why?
Delivery of Health Care, Integrated
2
2018
293
0.040
 Why?
Information Dissemination
1
2004
224
0.040
 Why?
Women's Health
1
2004
311
0.040
 Why?
Sodium
1
2022
196
0.040
 Why?
Kidney Diseases
1
2005
409
0.040
 Why?
Academic Medical Centers
1
2024
531
0.040
 Why?
Vitamin K 1
1
2000
3
0.040
 Why?
Acute Disease
1
2004
1010
0.040
 Why?
Postmenopause
1
2003
371
0.040
 Why?
Symptom Flare Up
1
2020
38
0.040
 Why?
Medical Audit
2
2013
78
0.040
 Why?
Aftercare
1
2022
218
0.040
 Why?
Health Plan Implementation
1
2021
145
0.040
 Why?
Antifibrinolytic Agents
1
2000
57
0.040
 Why?
Liver Diseases
1
2003
301
0.040
 Why?
Europe
1
2020
411
0.040
 Why?
Patient Satisfaction
1
2004
697
0.040
 Why?
Rivaroxaban
1
2021
259
0.040
 Why?
Predictive Value of Tests
1
2005
2075
0.040
 Why?
Ibuprofen
1
1999
83
0.040
 Why?
Kidney Function Tests
1
2019
159
0.040
 Why?
Administration, Oral
1
2021
803
0.040
 Why?
Societies, Scientific
1
2019
51
0.040
 Why?
Drug Hypersensitivity
1
2000
95
0.040
 Why?
Blood Coagulation
1
2000
269
0.040
 Why?
Neoplasms
1
2014
2747
0.040
 Why?
Student Health Services
1
2018
16
0.040
 Why?
Child
2
2017
22414
0.040
 Why?
Software
1
2023
678
0.030
 Why?
Antiretroviral Therapy, Highly Active
1
1999
285
0.030
 Why?
Self Care
1
2000
395
0.030
 Why?
United States Department of Veterans Affairs
1
2022
711
0.030
 Why?
Glucose
1
2022
1041
0.030
 Why?
Hospitals
1
2022
696
0.030
 Why?
Homozygote
1
2017
201
0.030
 Why?
Felodipine
1
1996
4
0.030
 Why?
Receptors, Drug
1
1996
13
0.030
 Why?
Cost-Benefit Analysis
1
2019
619
0.030
 Why?
Drug Monitoring
2
2010
399
0.030
 Why?
Public Health
1
2021
587
0.030
 Why?
Polypharmacy
1
2016
89
0.030
 Why?
Calcium Channels
1
1996
156
0.030
 Why?
Patient Discharge
1
2022
933
0.030
 Why?
Cross-Over Studies
1
1997
582
0.030
 Why?
Myocardial Ischemia
1
1996
280
0.030
 Why?
Communication
2
2014
951
0.030
 Why?
Data Interpretation, Statistical
1
1996
377
0.030
 Why?
Pain
1
1999
781
0.030
 Why?
Regression Analysis
2
2009
1023
0.030
 Why?
Clinical Decision-Making
1
2016
339
0.030
 Why?
Antibodies, Monoclonal, Humanized
1
2019
913
0.020
 Why?
Infant
2
2004
9843
0.020
 Why?
Hemodynamics
1
1997
1100
0.020
 Why?
Comprehension
1
2014
183
0.020
 Why?
Adrenergic Antagonists
1
2011
6
0.020
 Why?
Educational Status
1
2014
464
0.020
 Why?
Phytotherapy
1
2011
82
0.020
 Why?
Health Planning Guidelines
1
2010
25
0.020
 Why?
Poisson Distribution
1
2010
77
0.020
 Why?
Prospective Studies
3
2015
7777
0.020
 Why?
Breast Neoplasms
1
2003
2257
0.020
 Why?
Likelihood Functions
1
2010
147
0.020
 Why?
Models, Organizational
1
2011
147
0.020
 Why?
Anti-Bacterial Agents
1
2000
1866
0.020
 Why?
Preferred Provider Organizations
1
2009
4
0.020
 Why?
Pilot Projects
1
2015
1826
0.020
 Why?
Transportation
1
2009
52
0.020
 Why?
Private Sector
1
2009
53
0.020
 Why?
Case-Control Studies
1
2016
3597
0.020
 Why?
Phenotype
1
2017
3177
0.020
 Why?
Infliximab
1
2009
111
0.020
 Why?
Interprofessional Relations
1
2011
292
0.020
 Why?
North America
1
2009
307
0.020
 Why?
Cooperative Behavior
1
2011
463
0.020
 Why?
Quality of Life
1
2019
3014
0.020
 Why?
Multivariate Analysis
1
2010
1498
0.020
 Why?
Organizational Policy
1
2006
84
0.020
 Why?
Professional Practice
1
2006
63
0.010
 Why?
Health Care Costs
1
2009
427
0.010
 Why?
Role
1
2005
30
0.010
 Why?
Time Factors
1
1996
6966
0.010
 Why?
Logistic Models
1
2010
2092
0.010
 Why?
Expert Testimony
1
2005
44
0.010
 Why?
Bone Diseases, Metabolic
1
2005
64
0.010
 Why?
Interdisciplinary Communication
1
2005
193
0.010
 Why?
Diabetes Complications
1
2005
224
0.010
 Why?
Review Literature as Topic
1
2004
72
0.010
 Why?
Models, Economic
1
2004
60
0.010
 Why?
Probability
1
2004
309
0.010
 Why?
Venlafaxine Hydrochloride
1
2002
15
0.010
 Why?
Menstruation
1
2002
42
0.010
 Why?
International Normalized Ratio
1
2000
48
0.010
 Why?
Health Maintenance Organizations
1
2000
107
0.010
 Why?
beta-Lactams
1
2000
34
0.010
 Why?
Medical Records
1
2000
182
0.010
 Why?
Hospitalization
1
2009
2264
0.010
 Why?
Sensitivity and Specificity
1
2004
1977
0.010
 Why?
Depressive Disorder
1
2002
395
0.010
 Why?
Prevalence
1
2005
2799
0.010
 Why?
Depression
1
2004
1508
0.010
 Why?
Saseen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (461) concept(s)
_
Co-Authors Expand Description
See all (54) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)